BioAtla shares surge 21.24% premarket after regulatory update on Ozuriftamab Vedotin clinical plan following productive FDA Type B meeting.

BioAtla (NASDAQ:BCAB) surged 21.24% in premarket trading following a regulatory update on its clinical development plan for ozuriftamab vedotin in oropharyngeal squamous cell carcinoma (OPSCC) after a productive Type B meeting with the FDA. The news, released one hour prior to the price movement, indicated favorable feedback from the agency, reinforcing confidence in the drug’s development trajectory. While older news included downgrades and restructuring, the immediate premarket jump aligns with the fresh regulatory optimism, overshadowing prior bearish signals.